Your browser is no longer supported. Please, upgrade your browser.
Settings
RGLS [NASD]
Regulus Therapeutics Inc.
Index- P/E- EPS (ttm)-0.39 Insider Own0.50% Shs Outstand71.29M Perf Week-23.62%
Market Cap70.51M Forward P/E- EPS next Y-0.34 Insider Trans-2.58% Shs Float71.22M Perf Month5.89%
Income-15.80M PEG- EPS next Q-0.08 Inst Own49.70% Short Float8.31% Perf Quarter-46.45%
Sales10.00M P/S7.05 EPS this Y58.20% Inst Trans30.89% Short Ratio2.10 Perf Half Y-16.05%
Book/sh0.38 P/B2.45 EPS next Y-3.00% ROA-47.00% Target Price1.17 Perf Year-0.88%
Cash/sh0.42 P/C2.23 EPS next 5Y39.60% ROE-91.00% 52W Range0.42 - 2.32 Perf YTD-30.98%
Dividend- P/FCF- EPS past 5Y49.00% ROI-46.10% 52W High-59.84% Beta2.27
Dividend %- Quick Ratio3.70 Sales past 5Y-13.60% Gross Margin- 52W Low120.70% ATR0.11
Employees23 Current Ratio3.70 Sales Q/Q- Oper. Margin- RSI (14)40.47 Volatility17.01% 10.24%
OptionableYes Debt/Eq0.17 EPS Q/Q65.80% Profit Margin- Rel Volume2.11 Prev Close0.99
ShortableYes LT Debt/Eq0.00 EarningsMay 13 AMC Payout- Avg Volume2.81M Price0.93
Recom2.70 SMA20-10.10% SMA50-19.32% SMA200-10.86% Volume6,037,143 Change-5.66%
Mar-28-18Initiated B. Riley FBR, Inc. Neutral $1
Jan-05-18Initiated Leerink Partners Outperform $2
Jun-13-17Reiterated Chardan Capital Markets Buy $5 → $2.50
Mar-06-17Reiterated Wedbush Outperform $8 → $6
Jan-30-17Downgrade Wells Fargo Outperform → Market Perform
Jan-30-17Downgrade Needham Buy → Hold
Dec-07-16Reiterated Chardan Capital Markets Buy $12 → $5
Nov-02-16Reiterated Needham Buy $10 → $9
Jul-25-16Reiterated Chardan Capital Markets Buy $14.50 → $12
Jun-28-16Reiterated Needham Buy $25 → $10
Jun-28-16Reiterated FBR Capital Outperform $30 → $9
Jun-28-16Reiterated Chardan Capital Markets Buy $20 → $13.50
Jun-07-16Reiterated Chardan Capital Markets Buy $15 → $20
Apr-13-16Initiated Chardan Capital Markets Buy $15
Dec-04-15Initiated Wells Fargo Outperform
Jun-09-15Initiated Guggenheim Buy
Apr-21-15Resumed FBR Capital Outperform $30
Nov-24-14Initiated Deutsche Bank Buy $30
Aug-07-14Reiterated FBR Capital Outperform $14 → $15
Aug-14-13Reiterated Needham Buy $8 → $12
Jun-11-21 08:56AM  
May-21-21 10:47AM  
08:07AM  
May-14-21 04:07PM  
May-13-21 05:35PM  
04:07PM  
03:15PM  
May-06-21 03:01PM  
May-03-21 09:25AM  
08:00AM  
Apr-15-21 08:07AM  
Apr-07-21 08:07AM  
Mar-10-21 04:03AM  
Mar-09-21 04:07PM  
Mar-05-21 04:07PM  
Mar-04-21 12:30PM  
Feb-10-21 08:07AM  
Jan-27-21 08:07AM  
Jan-05-21 08:07AM  
Dec-09-20 08:54AM  
Dec-08-20 08:07AM  
Dec-02-20 07:00AM  
Dec-01-20 08:35AM  
Nov-29-20 02:33PM  
Nov-05-20 05:25PM  
04:07PM  
Nov-03-20 12:31PM  
Nov-02-20 08:07AM  
Oct-15-20 08:07AM  
Oct-13-20 08:07AM  
Sep-11-20 08:07AM  
Sep-08-20 08:28AM  
Sep-03-20 08:07AM  
Aug-31-20 08:07AM  
Aug-13-20 06:05PM  
04:07PM  
Aug-06-20 12:30PM  
08:07AM  
Aug-03-20 08:07AM  
Jul-29-20 08:07AM  
Jul-22-20 08:07AM  
Jun-12-20 08:01AM  
May-14-20 04:07PM  
May-07-20 12:30PM  
Mar-12-20 04:37PM  
Mar-09-20 12:30PM  
Feb-13-20 04:30PM  
Jan-21-20 07:47AM  
Dec-22-19 07:44PM  
Dec-16-19 08:00AM  
Nov-18-19 08:07AM  
Nov-15-19 01:37PM  
Nov-12-19 05:55PM  
04:05PM  
Nov-07-19 10:30AM  
Oct-16-19 04:15PM  
Sep-20-19 01:30PM  
Sep-12-19 08:00AM  
Sep-03-19 04:10PM  
Aug-29-19 04:10PM  
Aug-08-19 07:20PM  
04:10PM  
Aug-06-19 02:50PM  
Aug-01-19 10:33AM  
Jul-30-19 08:00AM  
Jul-29-19 11:33AM  
Jul-23-19 06:30PM  
Jun-11-19 05:00AM  
May-10-19 05:39AM  
May-09-19 04:05PM  
May-07-19 04:05PM  
May-06-19 09:15AM  
09:00AM  
May-02-19 10:32AM  
Apr-08-19 08:00AM  
Mar-28-19 09:45AM  
Mar-18-19 08:53AM  
08:00AM  
Mar-15-19 06:00PM  
Jan-07-19 08:00AM  
Jan-04-19 04:05PM  
Dec-20-18 09:56AM  
Nov-28-18 07:35AM  
Nov-19-18 08:00AM  
Nov-08-18 06:40PM  
05:38PM  
04:05PM  
Nov-06-18 07:30AM  
Oct-25-18 04:05PM  
Oct-23-18 11:30AM  
08:35AM  
Oct-22-18 04:05PM  
Oct-18-18 04:05PM  
Oct-17-18 07:45AM  
Oct-04-18 08:05AM  
Oct-02-18 04:05PM  
Sep-27-18 04:05PM  
Sep-26-18 04:05PM  
Sep-19-18 02:22PM  
Aug-23-18 12:50PM  
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase 1 development for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products, which include RGLS5579 glioblastoma multiforme program; and Hepatitis B virus, non-alcoholic steatohepatitis, and cell therapies programs. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hagan Joseph PPresident and CEOMay 17Sale0.894,1863,726316,292May 17 07:13 PM
Aker Christopher RaySr. VP & General CounselMay 17Sale0.8986076541,754May 17 07:12 PM
Aker Christopher RaySr. VP & General CounselFeb 16Sale1.728281,42442,614Feb 17 05:23 PM
Hagan Joseph PPresident and CEOFeb 16Sale1.724,1447,128485,756Feb 17 05:23 PM
Sonsini Peter W.10% OwnerDec 04Buy0.624,398,6022,735,9306,451,056Dec 07 05:13 PM
Walker Paul Edward10% OwnerDec 04Buy0.624,398,6022,735,9306,451,056Dec 07 05:14 PM
SANDELL SCOTT D10% OwnerDec 04Buy0.624,398,6022,735,9306,451,056Dec 07 05:12 PM
MAKOWER JOSHUA10% OwnerDec 04Buy0.624,398,6022,735,9306,451,056Dec 07 05:12 PM
Florence Anthony A. Jr.10% OwnerDec 04Buy0.624,398,6022,735,9306,451,056Dec 07 05:10 PM
Makhzoumi Mohamad10% OwnerDec 04Buy0.624,398,6022,735,9306,451,056Dec 07 05:11 PM
Chang Carmen10% OwnerDec 04Buy0.624,398,6022,735,9306,451,056Dec 07 05:10 PM
Behbahani Ali10% OwnerDec 04Buy0.624,398,6022,735,9306,451,056Dec 07 05:09 PM
BASKETT FOREST10% OwnerDec 04Buy0.624,398,6022,735,9306,451,056Dec 07 05:08 PM
Growth Equity Opportunities V,10% OwnerDec 04Buy0.624,398,6022,735,9306,451,056Dec 07 05:06 PM
Aker Christopher RaySr. VP & General CounselNov 16Sale0.5287645625,762Nov 18 04:10 PM
Hagan Joseph PPresident and CEONov 16Sale0.526,0943,176215,994Nov 18 04:09 PM
Aker Christopher RaySr. VP & General CounselAug 14Sale0.6087252826,638Aug 17 08:21 PM
Hagan Joseph PPresident and CEOAug 14Sale0.604,2452,568222,088Aug 17 08:22 PM